Skip to main content
. 2020 Sep 14;106(11):2906–2917. doi: 10.3324/haematol.2020.254193

Figure 4.

Figure 4.

Combinatorial effect of ATR inhibition and splicing modulation on splicing factor mutated and non-mutated myelodysplastic syndrome CD 34+ cells. (A) Dose-response experiment measuring cell viability at 48 hour after continuous drug exposure towards Pladienolide B; n=3 (healthy old), n=3 (nonsf mutated), n=3 (sf mutated) myelodysplastic syndrome (MDS) patients. (B) Cells were exposed to 500 nM AZD6738, 5 nM Pladienolide B, or a combination of both, and viability was determined by CellTiter-Glo® 48 hours after continuous drug exposure in vitro; n=5 (non-sf mutated patients), n=14 (sf mutated patients). (C) Combinatorial effect of ATR inhibition and splicing modulation on ZRSR2 mutated MDS CD34+ cells (UPN48) (n=3 technical replicates of one patient). Data are means +/- standard deviation. *P≤0.05; ** P≤0.01; ***P≤0.001; n.s.: not significant; sf: splicing factor; PladB: Pladienolide B; UPN: unique patient number.